Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Challenges in the development of glaucoma neuroprotection therapy.

Liu Y, Pang IH.

Cell Tissue Res. 2013 Aug;353(2):253-60. doi: 10.1007/s00441-013-1584-z. Epub 2013 Mar 10. Review.

PMID:
23474740
2.

Clinical trials in neuroprotection.

Whitcup SM.

Prog Brain Res. 2008;173:323-35. doi: 10.1016/S0079-6123(08)01123-0. Review.

PMID:
18929119
3.

Erythropoietin: a candidate neuroprotective agent in the treatment of glaucoma.

Tsai JC, Song BJ, Wu L, Forbes M.

J Glaucoma. 2007 Sep;16(6):567-71. Review.

PMID:
17873720
4.

Is neuroprotection a viable therapy for glaucoma?

Weinreb RN, Levin LA.

Arch Ophthalmol. 1999 Nov;117(11):1540-4. Review.

PMID:
10565524
5.

Disease progression and the need for neuroprotection in glaucoma management.

Varma R, Peeples P, Walt JG, Bramley TJ.

Am J Manag Care. 2008 Feb;14(1 Suppl):S15-9. Review.

6.

Beyond intraocular pressure: neuroprotective strategies for future glaucoma therapy.

Hartwick AT.

Optom Vis Sci. 2001 Feb;78(2):85-94. Review.

PMID:
11265931
7.

History of neuroprotection and rationale as a therapy for glaucoma.

Levin LA, Peeples P.

Am J Manag Care. 2008 Feb;14(1 Suppl):S11-4. Review.

8.

Neuroprotection in glaucoma: a model for neuroprotection in optic neuropathies.

Marcic TS, Belyea DA, Katz B.

Curr Opin Ophthalmol. 2003 Dec;14(6):353-6. Review.

PMID:
14615639
9.

Pharmacological neuroprotection for glaucoma.

Chidlow G, Wood JP, Casson RJ.

Drugs. 2007;67(5):725-59. Review.

PMID:
17385943
10.

In glaucoma, should enthusiasm about neuroprotection be tempered by the experience obtained in other neurodegenerative disorders?

Haefliger IO, Fleischhauer JC, Flammer J.

Eye (Lond). 2000 Jun;14 ( Pt 3B):464-72. Review.

PMID:
11026975
11.

Animal and culture models of glaucoma for studying neuroprotection.

Levin LA.

Eur J Ophthalmol. 2001 Jul-Sep;11 Suppl 2:S23-9. Review.

PMID:
11592527
12.

Neuroprotection in glaucoma: recent and future directions.

Danesh-Meyer HV.

Curr Opin Ophthalmol. 2011 Mar;22(2):78-86. doi: 10.1097/ICU.0b013e32834372ec. Review.

PMID:
21252670
13.

Current and emerging medical therapies in the treatment of glaucoma.

Bagnis A, Papadia M, Scotto R, Traverso CE.

Expert Opin Emerg Drugs. 2011 Jun;16(2):293-307. doi: 10.1517/14728214.2011.563733. Epub 2011 Apr 7. Review.

PMID:
21406029
14.

Clinical trials for glaucoma neuroprotection are not impossible.

Quigley HA.

Curr Opin Ophthalmol. 2012 Mar;23(2):144-54. doi: 10.1097/ICU.0b013e32834ff490. Review.

PMID:
22249238
15.

Translational neuroprotection research in glaucoma: a review of definitions and principles.

Casson RJ, Chidlow G, Ebneter A, Wood JP, Crowston J, Goldberg I.

Clin Exp Ophthalmol. 2012 May-Jun;40(4):350-7. doi: 10.1111/j.1442-9071.2011.02563.x. Epub 2011 Apr 27. Review.

PMID:
22697056
16.

Antiglaucoma pharmacotherapy.

Tătaru CP, Purcărea VL.

J Med Life. 2012 Sep 15;5(3):247-51. Epub 2012 Sep 25. Review.

17.

Biomarkers and surrogate endpoints in glaucoma clinical trials.

Medeiros FA.

Br J Ophthalmol. 2015 May;99(5):599-603. doi: 10.1136/bjophthalmol-2014-305550. Epub 2014 Jul 17. Review.

18.

Neuroprotective therapies in glaucoma: I. Neurotrophic factor delivery.

Nafissi N, Foldvari M.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016 Mar-Apr;8(2):240-54. doi: 10.1002/wnan.1361. Epub 2015 Aug 26. Review.

PMID:
26306832
19.

Obstacles to the development of a neuroprotective therapy for Parkinson's disease.

Stocchi F, Olanow CW.

Mov Disord. 2013 Jan;28(1):3-7. doi: 10.1002/mds.25337. Review.

PMID:
23390094
20.

Supplemental Content

Support Center